<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04664790</url>
  </required_header>
  <id_info>
    <org_study_id>275-20-ASF</org_study_id>
    <nct_id>NCT04664790</nct_id>
  </id_info>
  <brief_title>Hyperbaric Oxygen Therapy Compared to Cognitive Training in FASD</brief_title>
  <official_title>Hyperbaric Oxygen Therapy vs. Cognitive Training for Fetal Alcohol Spectrum Disorder; A Prospective, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fetal Alcohol Spectrum Disorder (FASD) describes a wide range of adverse physical, behavioral&#xD;
      and cognitive effects resulting from prenatal alcohol exposure (PAE) during embryonic and&#xD;
      fetal development. A number of clinical studies have presented evidence regarding the&#xD;
      physiological effects of HBOT on metabolically dysfunctional brain regions that might be&#xD;
      related to FASD. The aim of the study is to compare the effect of HBOT vs. neurocognitive&#xD;
      training on neurobehavioral function in FASD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fetal Alcohol Spectrum Disorder (FASD) describes a wide range of adverse physical, behavioral&#xD;
      and cognitive effects resulting from prenatal alcohol exposure (PAE) during embryonic and&#xD;
      fetal development. Currently individuals afflicted by FASD are treated symptomatically for&#xD;
      ADHD and different forms of disruptive behavior. However, these approaches have not succeeded&#xD;
      in improving the long-term clinical outcome [1].&#xD;
&#xD;
      A number of clinical studies have presented evidence regarding the physiological effects of&#xD;
      hyperbaric oxygen therapy (HBOT) on metabolically dysfunctional brain regions that might be&#xD;
      related to FASD [2-5]. Case studies conducted using HBOT suggested a potential safe and&#xD;
      efficient treatment for FESD [6-7]. The aim of the study is to compare the effect of HBOT vs.&#xD;
      neurocognitive training on neurobehavioral function in FASD.&#xD;
&#xD;
      The study is designed as a prospective randomized, two active arm trial. After enrolment,&#xD;
      eligible participants will be randomized with equal probability into one of two arms: HBOT or&#xD;
      cognitive training arm. The evaluation procedure will be performed twice, at baseline and 1-3&#xD;
      weeks after the last treatment session, and includes cognitive tests, FASD relegated&#xD;
      questionnaires, and anatomical and functional brain imaging (MRI and SPECT). The study is&#xD;
      designed as an intention to treat trial, and thus, patients will be included in the analysis&#xD;
      if they completed at least one HBOT/cognitive training session, and attained post treatment&#xD;
      study analysis.&#xD;
&#xD;
      The HBOT protocol will be administrated in a multi-place chamber. The protocol comprised of&#xD;
      60 daily sessions, 5 sessions per week within a three month period. Each session includes&#xD;
      breathing 100% oxygen by mask at 2ATA for 90 minutes with 5-minute air breaks every 20&#xD;
      minutes.&#xD;
&#xD;
      The cognitive training protocol contains a neuropsychologist guided BrainHQ training program.&#xD;
      This is a 3 months program that includes 30 minutes sessions at least 3 times per week.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive health assessment (NeuroTrax)</measure>
    <time_frame>baseline, 3 months</time_frame>
    <description>Memory, attention and information process will be evaluated using the NeuroTrax computerized cognitive evaluation battery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Executive functions and self-regulation in everyday environment</measure>
    <time_frame>baseline, 3 months</time_frame>
    <description>Evaluated using the Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) self-reported questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain perfusion</measure>
    <time_frame>baseline, 3 months</time_frame>
    <description>Cerebral blood volume and flow will be measured using perfusion MRI protocol Dynamic susceptibility contrast (DSC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain microstructure</measure>
    <time_frame>baseline, 3 months</time_frame>
    <description>Mean diffusivity (MD) will be evaluated using diffusion tensor imaging (DTI) MRI protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain microstructure</measure>
    <time_frame>baseline, 3 months</time_frame>
    <description>Fractional anisotropy (FA) will be evaluated using diffusion tensor imaging (DTI) MRI protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain function imaging</measure>
    <time_frame>baseline, 3 months</time_frame>
    <description>Resting state fMRI (rsfMRI), and task based fmri will evaluate brain function during a working memory task.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Brain function imaging</measure>
    <time_frame>baseline, 3 months</time_frame>
    <description>Brain Single photon emission computed tomography (SPECT) will be conducted using Tc-99m-ECD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression anxiety and stress</measure>
    <time_frame>baseline, 3 months, 6 months</time_frame>
    <description>Evaluated using the Depression Anxiety Stress Scale Test (DASS 21) self-report instrument.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interpersonal Reactive Index (IRI)</measure>
    <time_frame>baseline, 3 months, 6 months</time_frame>
    <description>The IRI questionnaire will be used to evaluate cognitive and affective aspects of empathic abilities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difficulties in Emotion Regulation Scale (DERS)</measure>
    <time_frame>baseline, 3 months, 6 months</time_frame>
    <description>The DERS questionnaire is a multidimensional self-report measure of emotion regulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mental Health Continuum (MHC-SF)</measure>
    <time_frame>baseline, 3 months, 6 months</time_frame>
    <description>The MHC-SF questionnaire will be used to assess three components of well-being: emotional, social, and psychological and conduct categorical diagnosis of positive mental health.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>FASD</condition>
  <arm_group>
    <arm_group_label>Hyperbaric Oxygen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognitive training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neuropsychologist guided cognitive training.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyperbaric Oxygen</intervention_name>
    <description>Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes</description>
    <arm_group_label>Hyperbaric Oxygen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive training</intervention_name>
    <description>Neuropsychologist guided BrainHQ training</description>
    <arm_group_label>Cognitive training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject willing and able to sign an informed consent&#xD;
&#xD;
          -  Age 18 years and older&#xD;
&#xD;
          -  Diagnosed with FASD by an Israeli expert&#xD;
&#xD;
          -  Failure to improve after at least one line of conventional therapy&#xD;
&#xD;
          -  Stable psychological and pharmacological treatment for over three months prior to&#xD;
             inclusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to attend scheduled clinic visits and/or comply with the study protocol&#xD;
&#xD;
          -  History of other brain pathologies&#xD;
&#xD;
          -  Active malignancy&#xD;
&#xD;
          -  Serious suicidal ideation&#xD;
&#xD;
          -  Severe or unstable physical disorders at baseline&#xD;
&#xD;
          -  History of HBOT for any reason prior to study enrollment&#xD;
&#xD;
          -  Chest pathology incompatible with pressure changes (including active asthma)&#xD;
&#xD;
          -  Inner ear disease&#xD;
&#xD;
          -  Contraindications for MRI or inability to perform an awake brain MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shai Efrati, Prof</last_name>
    <phone>97289779393</phone>
    <email>efratishai@outlook.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assaf-Harofeh Medical Center</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Goodlett CR, Horn KH. Mechanisms of alcohol-induced damage to the developing nervous system. Alcohol Res Health. 2001;25(3):175-84. Review.</citation>
    <PMID>11810955</PMID>
  </reference>
  <reference>
    <citation>Efrati S, Ben-Jacob E. Reflections on the neurotherapeutic effects of hyperbaric oxygen. Expert Rev Neurother. 2014 Mar;14(3):233-6. doi: 10.1586/14737175.2014.884928. Epub 2014 Jan 29.</citation>
    <PMID>24471697</PMID>
  </reference>
  <reference>
    <citation>Efrati S, Fishlev G, Bechor Y, Volkov O, Bergan J, Kliakhandler K, Kamiager I, Gal N, Friedman M, Ben-Jacob E, Golan H. Hyperbaric oxygen induces late neuroplasticity in post stroke patients--randomized, prospective trial. PLoS One. 2013;8(1):e53716. doi: 10.1371/journal.pone.0053716. Epub 2013 Jan 15.</citation>
    <PMID>23335971</PMID>
  </reference>
  <reference>
    <citation>Hadanny A, Bechor Y, Catalogna M, Daphna-Tekoah S, Sigal T, Cohenpour M, Lev-Wiesel R, Efrati S. Hyperbaric Oxygen Therapy Can Induce Neuroplasticity and Significant Clinical Improvement in Patients Suffering From Fibromyalgia With a History of Childhood Sexual Abuse-Randomized Controlled Trial. Front Psychol. 2018 Dec 17;9:2495. doi: 10.3389/fpsyg.2018.02495. eCollection 2018.</citation>
    <PMID>30618929</PMID>
  </reference>
  <reference>
    <citation>Hadanny A, Rittblat M, Bitterman M, May-Raz I, Suzin G, Boussi-Gross R, Zemel Y, Bechor Y, Catalogna M, Efrati S. Hyperbaric oxygen therapy improves neurocognitive functions of post-stroke patients - a retrospective analysis. Restor Neurol Neurosci. 2020;38(1):93-107. doi: 10.3233/RNN-190959.</citation>
    <PMID>31985478</PMID>
  </reference>
  <reference>
    <citation>Stoller KP. Quantification of neurocognitive changes before, during, and after hyperbaric oxygen therapy in a case of fetal alcohol syndrome. Pediatrics. 2005 Oct;116(4):e586-91. Epub 2005 Sep 15.</citation>
    <PMID>16166387</PMID>
  </reference>
  <reference>
    <citation>Koren G, Golan C, Suzin G, Berkovich M, Efrati S. Effects of Hyperbaric Oxygen Therapy on Brain Perfusion, Cognition and Behavior in Fetal Alcohol Spectrum Disorder-A Case Study. Alcohol Alcohol. 2019 Mar 1;54(2):177-179. doi: 10.1093/alcalc/agz009.</citation>
    <PMID>30801636</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

